CO5140093A1 - Epotilonas c 21 modificadas - Google Patents

Epotilonas c 21 modificadas

Info

Publication number
CO5140093A1
CO5140093A1 CO00012008A CO00012008A CO5140093A1 CO 5140093 A1 CO5140093 A1 CO 5140093A1 CO 00012008 A CO00012008 A CO 00012008A CO 00012008 A CO00012008 A CO 00012008A CO 5140093 A1 CO5140093 A1 CO 5140093A1
Authority
CO
Colombia
Prior art keywords
epotilones
modified
jpeg
mfi
emi file
Prior art date
Application number
CO00012008A
Other languages
English (en)
Inventor
Gregory D Vite
Sonng-Hoon Kim
Gerhard Hofle
Nicole Glaser
Thomas Leibold
Original Assignee
Bristol Myers Squibb Co
Biotechnolog Forschung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de
Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de
Application filed by Bristol Myers Squibb Co, Biotechnolog Forschung Gmbh filed Critical Bristol Myers Squibb Co
Publication of CO5140093A1 publication Critical patent/CO5140093A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Abstract

El compuesto que tiene la fórmula general I<EMI FILE="00012008_1" ID="1" IMF=JPEG >caracterizado porqueP-Q es un doble enlace C, C o un epóxido,G es<EMI FILE="00012008_2" ID="2" IMF=JPEG >R se selecciona del grupo de H, alquilo o alquilo substituido;R1 se selecciona del grupo que consiste de<EMI FILE="00012008_3" ID="3" IMF=JPEG >
CO00012008A 1999-02-22 2000-02-22 Epotilonas c 21 modificadas CO5140093A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999107588 DE19907588A1 (de) 1999-02-22 1999-02-22 C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de) 1999-07-01 1999-07-01 C-21 Modifizierte Epothilone

Publications (1)

Publication Number Publication Date
CO5140093A1 true CO5140093A1 (es) 2002-03-22

Family

ID=26051995

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00012008A CO5140093A1 (es) 1999-02-22 2000-02-22 Epotilonas c 21 modificadas

Country Status (37)

Country Link
US (1) US6262094B1 (es)
EP (1) EP1157023B1 (es)
JP (1) JP4598957B2 (es)
KR (1) KR100685336B1 (es)
CN (1) CN1205208C (es)
AR (1) AR028815A1 (es)
AT (1) ATE254615T1 (es)
AU (1) AU771089B2 (es)
BG (1) BG64987B1 (es)
BR (1) BR0008379A (es)
CA (1) CA2360452C (es)
CO (1) CO5140093A1 (es)
CZ (1) CZ301498B6 (es)
DE (1) DE60006649T2 (es)
DK (1) DK1157023T3 (es)
EE (1) EE04852B1 (es)
ES (1) ES2209831T3 (es)
GE (1) GEP20033067B (es)
HK (1) HK1038923B (es)
HU (1) HUP0200076A3 (es)
ID (1) ID29829A (es)
IL (1) IL144501A0 (es)
LT (1) LT4944B (es)
LV (1) LV12755B (es)
MX (1) MXPA01008374A (es)
MY (1) MY120601A (es)
NO (1) NO320806B1 (es)
NZ (1) NZ513629A (es)
PE (1) PE20001546A1 (es)
PL (1) PL212545B1 (es)
PT (1) PT1157023E (es)
RU (1) RU2253652C2 (es)
SK (1) SK287200B6 (es)
TR (1) TR200102401T2 (es)
TW (1) TWI270546B (es)
UY (1) UY26024A1 (es)
WO (1) WO2000050423A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59712968D1 (de) * 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
AU756699B2 (en) * 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
BR0114065A (pt) 2000-09-22 2003-07-22 Biotechnolog Forschung Gmbh Triazolo-epotilonas
EP1414384A4 (en) * 2000-10-13 2005-07-27 Univ Mississippi SYNTHESIS OF EPOTHILONES AND RELATED ANALOGS
KR20030071853A (ko) * 2001-01-25 2003-09-06 브리스톨-마이어스스퀴브컴파니 에포틸론 유사체를 함유한 비경구용 제제
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EE200300397A (et) * 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaadid refraktaarsete kasvajate raviks
RU2003128311A (ru) 2001-02-20 2005-03-10 Бристол-Маерс Сквибб Компани (Us) Способ лечения резистентных опухолей с применением аналогов эпотилона
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
IL162595A0 (en) * 2002-01-14 2005-11-20 Novartis Ag Combinations comprising epothilones and antimetabolites
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003212457A1 (en) * 2002-03-01 2003-09-16 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
CN1939299A (zh) * 2002-03-08 2007-04-04 诺瓦提斯公司 包含埃坡霉素衍生物和烷化剂的组合
SI1485090T1 (sl) * 2002-03-08 2008-06-30 Novartis Ag Kombinacija vključujoča derivat epotilona in imidazotetrazinon
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
US6719540B2 (en) 2002-03-12 2004-04-13 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
EP1503756B1 (en) * 2002-05-01 2009-08-12 Novartis AG Epothilone derivative for the treatment of hepatoma and other cancer diseases
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004018478A2 (en) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004026254A2 (en) 2002-09-23 2004-04-01 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
MXPA05003706A (es) * 2002-10-09 2005-07-01 Kosan Biosciences Inc Epo d+5-fu/gemcitabina.
ATE479667T1 (de) 2003-02-06 2010-09-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
RU2349319C1 (ru) * 2004-11-18 2009-03-20 Бристол-Маерс Сквибб Компани Гранула, покрытая энтеросолюбильной оболочкой, содержащая иксабепилон, и способ ее приготовления
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007062288A2 (en) * 2005-11-22 2007-05-31 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2008147941A1 (en) * 2007-05-25 2008-12-04 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
AU2009204194A1 (en) 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
CN102076339A (zh) * 2008-04-24 2011-05-25 百时美施贵宝公司 埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途
US20090311187A1 (en) * 2008-05-29 2009-12-17 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the Co-stimulatory pathway
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
EP2456790A1 (en) 2009-07-20 2012-05-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
MX352661B (es) 2009-11-05 2017-12-04 Rhizen Pharmaceuticals S A Star Moduladores novedosos de benzopiran cinasa.
ES2625637T3 (es) 2010-02-12 2017-07-20 Pharmascience Inc. Compuestos de unión al dominio BIR IAP
WO2011145035A1 (en) 2010-05-17 2011-11-24 Indian Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
WO2011146382A1 (en) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
CA2833935C (en) 2011-05-04 2020-09-15 Dhanapalan Nagarathnam Novel compounds as modulators of protein kinases
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
CA2865719C (en) 2012-03-30 2020-09-22 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
WO2014075391A1 (zh) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
CN107249632A (zh) 2014-12-04 2017-10-13 百时美施贵宝公司 用于治疗癌症(骨髓瘤)的抗cs1与抗pd‑1抗体的组合
EA035888B1 (ru) 2015-06-29 2020-08-27 Бристол-Майерс Сквибб Компани Режимы дозирования иммунотерапевтических средств и их комбинаций
CN105153177B (zh) * 2015-09-28 2017-08-08 湖南大学 呋喃并色满肟烯/炔丙基醚及其制备方法与应用
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE301115C (es)
DE75883C (de) W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen Ofen zur Erzeugung von Cyanammonium
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
ES2206607T3 (es) 1995-11-17 2004-05-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Derivados de epotilones, preparacion y utilizacion.
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE59712968D1 (de) * 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19707303B4 (de) 1997-02-11 2006-05-11 Mitteldeutsches Bitumenwerk Gmbh Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
PT975638E (pt) 1997-02-25 2002-12-31 Biotechnolog Forschung Mbh Gbf Epothilons modificados nas cadeias laterais
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (de) 1997-04-18 2002-10-09 Studiengesellschaft Kohle mbH Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
EP1001951B1 (de) 1997-07-16 2002-09-25 Schering Aktiengesellschaft Thiazolderivate, verfahren zur herstellung und verwendung
CA2299608A1 (en) 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
EP1140928A4 (en) * 1998-12-23 2002-10-02 Bristol Myers Squibb Co MICROBIAL CONVERSION METHOD FOR PRODUCING AN EPOTHILONE

Also Published As

Publication number Publication date
LV12755A (en) 2001-11-20
CA2360452A1 (en) 2000-08-31
CN1341114A (zh) 2002-03-20
NO320806B1 (no) 2006-01-30
HUP0200076A3 (en) 2003-01-28
SK287200B6 (sk) 2010-03-08
NO20014017D0 (no) 2001-08-17
LT2001086A (en) 2002-04-25
EE04852B1 (et) 2007-06-15
BR0008379A (pt) 2002-09-24
BG105830A (en) 2002-03-29
EP1157023A1 (en) 2001-11-28
HK1038923A1 (en) 2002-04-04
PT1157023E (pt) 2004-03-31
DE60006649D1 (de) 2003-12-24
PL212545B1 (pl) 2012-10-31
KR20010102199A (ko) 2001-11-15
KR100685336B1 (ko) 2007-02-23
ATE254615T1 (de) 2003-12-15
RU2253652C2 (ru) 2005-06-10
LT4944B (lt) 2002-08-26
UY26024A1 (es) 2000-09-29
WO2000050423A1 (en) 2000-08-31
NO20014017L (no) 2001-10-17
DK1157023T3 (da) 2004-03-29
SK10782001A3 (sk) 2002-03-05
HK1038923B (zh) 2004-03-19
CZ301498B6 (cs) 2010-03-24
CN1205208C (zh) 2005-06-08
JP4598957B2 (ja) 2010-12-15
IL144501A0 (en) 2002-05-23
JP2002537395A (ja) 2002-11-05
EE200100437A (et) 2002-12-16
DE60006649T2 (de) 2004-09-30
MXPA01008374A (es) 2003-06-06
ES2209831T3 (es) 2004-07-01
PE20001546A1 (es) 2001-03-18
GEP20033067B (en) 2003-09-25
HUP0200076A2 (hu) 2002-12-28
AU3234800A (en) 2000-09-14
ID29829A (id) 2001-10-11
TWI270546B (en) 2007-01-11
BG64987B1 (bg) 2006-11-30
AU771089B2 (en) 2004-03-11
NZ513629A (en) 2004-01-30
US6262094B1 (en) 2001-07-17
EP1157023B1 (en) 2003-11-19
CA2360452C (en) 2011-07-26
MY120601A (en) 2005-11-30
AR028815A1 (es) 2003-05-28
LV12755B (lv) 2002-04-20
PL350179A1 (en) 2002-11-18
CZ20012991A3 (cs) 2002-01-16
TR200102401T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
CO5140093A1 (es) Epotilonas c 21 modificadas
CO5271657A1 (es) Derivados de azaindol
CO5261589A1 (es) Compuestos heterociclicos, su produccion y su utilizacion
CO5160302A1 (es) INHIBIDORES DE aP2 DE BIFENILOS QUE CONTIENEN COMPUESTOS HETEROCICLICOS Y METODO
CO5400161A1 (es) Articulos agricolas
DE60208355D1 (de) 2-amino-propanol derivate
CO5310534A1 (es) Nuevos derivados de androstano anti-inflamatorios
CY1112569T1 (el) Παρασιτοκτονος επεξεργασια εδαφων ή υποστρωματων με θειωδεις ενωσεις
ES2195970T3 (es) L-ribavirina y usos de la misma.
IS6309A (is) Kínasólínafleiður
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
CO5251404A1 (es) Compuestos antibioticos de azalida
DE69021639D1 (de) Disäuren von Diarylstyrylchinolin.
DE60014080D1 (de) Halogenfreie flammhemmende zusammensetzung
CO5261566A1 (es) Compuestos antipicornavirales y composiciones, sus usos farmaceuticos y materiales para su sintesis
ATE347539T1 (de) Wässrige harzzusammensetzung
EA200200545A1 (ru) Онколитические комбинации для лечения рака
ATE316531T1 (de) Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
RS50229B (sr) Analozi vitamina d3
CO5261594A1 (es) Inhibidores de myt1 cinasa
EA200200727A1 (ru) Новые производные индола
AR027655A1 (es) Composiciones de resina que tienen alto contenido de solidos
CO5210860A1 (es) Nuevos derivados de pirimidina-2,4,6-triona
CO5080758A1 (es) DERIVADOS DE 3-(2-oxo-[1,3´]BIPIRROLODINIL-3-ILIDENMETIL
CO5261576A1 (es) Compuestos